期刊文献+

外科手术治疗老年非小细胞肺癌患者预后的影响因素分析 被引量:14

Prognostic factors of surgical treatment for elderly patients with non-small cell lung cancer
原文传递
导出
摘要 目的分析外科手术治疗老年非小细胞肺癌患者预后的影响因素,为改善患者预后提供理论基础。方法回顾性分析我院2012年1月至2014年9月手术治疗的145例老年非小细胞肺癌患者的临床资料并走访其生存情况。结果入选患者中位生存期为31.5个月,1年生存率61.4G,2年生存率45.5%,3年生存率40.0%。单因素分析结果表明,病灶大小、淋巴转移数量、临床分期、病理分型和放疗是影响患者预后的相关因素。多因素COX回归分析表明,病灶〉3cm、淋巴转移数量〉2个和病理分型为影响患者预后的独立危险因素,放疗为患者预后的保护因素。结论外科手术治疗老年非小细胞肺癌可获得较好的治疗效果,病灶大小、淋巴转移数量、病理分型和放疗是影响患者预后的重要因素,可为预后判断提高依据。 Objective To analyze prognostic factors of surgical treatment for elderly patients with non-small cell lung cancer, in order to provide a theoretic basis for improving the prognosis of patients with non-small cell lung cancer. Methods Clinical data of 145 elderly patients with non- small cell lung cancer who had received surgical treatment at our hospital from January 2012 to September 2012 were retrospectively analyzed. The survival rates of patients were investigated. Results The median survival time was 31.5 months, and 1-year, 2-year and 3 year survival rates were 61.4%, 45.5% and 40%, respectively. Single factor analysis showed that lesion size, number of metastatic lymph nodes, clinical stage, pathological type and radiotherapy were among the factors affecting prognosis. Multiple COX regression analysis showed that a lesion size 〉 3cm, number of lymph nodes with metastasis 〉 2 and pathological type were independent risk factors for patient prognosis, and radiotherapy was a protective factor for prognosis. Conclusions Surgical treatment has good curative effects on non-small cell lung cancer in elderly patients. Lesion size, number of lymph nodes with metastasis, pathological type and radiotherapy are important factors affecting prognosis, and can be used for prognosis
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2016年第3期260-262,共3页 Chinese Journal of Geriatrics
关键词 非小细胞肺 外科手术 预后 Carcinoma, non-small assessment. cell lung Surgery Prognosis
  • 相关文献

参考文献7

  • 1Li B, Liu J, Feng R, et al. The tumor-immune index is correlated with the prognosis of patients after curative resection for nonsmall cell lung cancer[J]. Medicine (Baltimore), 2015, 94 (48): e2174. DOI: 10. 1097/MD. 0000000000002174.
  • 2BluthgenMV, Besse I3. Second-line combination therapies in nonsmall cell lung cancer without known driver mutations[J]. Eur Respir Rev, 2015, 24 (138) : 582 593. DOI: 10. 1183/16000617. 00002115.
  • 3Remon J, Gorham J, Besse B, et al. Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients[J]. Eur Respir J, 2015,46 ( 6 ) : 1548 1550. DOI: 10. 1183/13993003. 01482-2015.
  • 4Jin J, Liu BZ, Wu ZM. Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptotyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment [J]. J Cancer Res Ther. 2015, 11 Suppl: C271-4. 1X)I.. 10. 4103/0973 1482. 170549.
  • 5Ju Y, Hu Y, Sun S, et al. Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy Chinese experiences [J ] . Indian J Cancer,2015, 52 Suppl: E32 E36. PA)I: 10.4103/ 0019 509X. 168954.
  • 6Yin X, Ying J, 1.i L, et al. A metaanalysis of lentinan injection combined with chemotherapy in the treatment of nonsmall cell lung cancer [J]. Indian J Cancer, 2015, 52 Suppl: E29-E31. DOI: 10. 4103/ 0019-509X. 168953.
  • 7Yoshino R, Imai H, Mori K, et al. Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer[J]. J Cancer Res Ther, 2015, 11 (3): 606-611. DOI: 10.4103/0973 1482. 163683.

同被引文献112

引证文献14

二级引证文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部